Literature DB >> 12749590

Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.

David Bishop-Bailey1, Jessica Wray.   

Abstract

Lipid mediators can exert their effects by interactions with well-characterised cell surface G-protein-linked receptors. Recently, a group of intracellular receptors have been identified that are activated by a large variety of lipid-derived mediators. Amongst these novel targets, the peroxisome proliferator-activated receptors (PPARs), a family of three (PPARalpha, beta/delta and gamma) nuclear receptor/transcription factors have become a major area for investigation. PPARs are found throughout the body, where they have diverse roles regulating lipid homeostasis, cellular differentiation, proliferation and the immune response. There is a great interest, therefore, in the roles of PPARs in a variety of pathological conditions, including diabetes, atherosclerosis, cancer and chronic inflammation. Although, a number of naturally occurring compounds can activate PPARs, it has been difficult, as yet, to characterise any of these mediators as truly endogenous ligands. These findings have lead to the suggestion that PPARs may act just as general lipid sensors. Acting as lipid sensors, PPARs may take changes in lipid/fatty acid balance in the diet or local metabolism and translate them to tissue-specific ligands, exerting tissue-specific effects. Using classical pharmacological criteria for endogenous mediator classification we will critically discuss the variety of pathways for putative ligand generation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12749590     DOI: 10.1016/s0090-6980(03)00003-0

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  28 in total

1.  Expression and activation of the farnesoid X receptor in the vasculature.

Authors:  David Bishop-Bailey; Desmond T Walsh; Timothy D Warner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-27       Impact factor: 11.205

2.  Fatty Acid-binding Proteins 1 and 2 Differentially Modulate the Activation of Peroxisome Proliferator-activated Receptor α in a Ligand-selective Manner.

Authors:  Maria L R Hughes; Bonan Liu; Michelle L Halls; Kylie M Wagstaff; Rahul Patil; Tony Velkov; David A Jans; Nigel W Bunnett; Martin J Scanlon; Christopher J H Porter
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

Review 3.  Role of Peroxisome Proliferator-Activated Receptor (PPAR)δ in Embryonic Stem Cell Proliferation.

Authors:  Min Young Lee; Yu Jin Lee; Yun Hee Kim; Sang Hun Lee; Jae Hong Park; Mi Ok Kim; Han Na Suh; Jung Min Ryu; Seung Pil Yun; Min Woo Jang; Ho Jae Han
Journal:  Int J Stem Cells       Date:  2009-05       Impact factor: 2.500

4.  Regio- and stereospecific syntheses and nitric oxide donor properties of (E)-9- and (E)-10-nitrooctadec-9-enoic acids.

Authors:  Michael J Gorczynski; Jinming Huang; S Bruce King
Journal:  Org Lett       Date:  2006-05-25       Impact factor: 6.005

Review 5.  Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.

Authors:  Richard Kones; Umme Rumana
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

6.  Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring.

Authors:  A E Kuriyan; G M Lehmann; A A Kulkarni; C F Woeller; S E Feldon; H B Hindman; P J Sime; K R Huxlin; R P Phipps
Journal:  Exp Eye Res       Date:  2011-12-08       Impact factor: 3.467

7.  The PPARgamma2 A/B-domain plays a gene-specific role in transactivation and cofactor recruitment.

Authors:  Anne Bugge; Lars Grøntved; Mads M Aagaard; Rehannah Borup; Susanne Mandrup
Journal:  Mol Endocrinol       Date:  2009-03-12

8.  Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts.

Authors:  Heather E Ferguson; Ajit Kulkarni; Geniece M Lehmann; Tatiana M Garcia-Bates; Thomas H Thatcher; Krystel R Huxlin; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2009-03-13       Impact factor: 6.914

Review 9.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

10.  The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo.

Authors:  Jessica A Wray; Mary C Sugden; Darryl C Zeldin; Gemma K Greenwood; Salma Samsuddin; Laura Miller-Degraff; J Alyce Bradbury; Mark J Holness; Timothy D Warner; David Bishop-Bailey
Journal:  PLoS One       Date:  2009-10-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.